Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients

References

• Chronic Kidney Disease Prognosis Consortium, Matsushita K, Van Der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–26.
   PubMed Web of Science ®Google Scholar
• Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.
   PubMed Web of Science ®Google Scholar
• Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110:32–35.
   PubMed Web of Science ®Google Scholar
• Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969–75.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Lott EH, Lu JL, et al. Outcomes associated with microalbuminuria: effect modification by chronic kidney disease. J Am Coll Cardiol. 2013;61:1626–33.
   PubMed Web of Science ®Google Scholar
• Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension. 2005;46:33–37.
   PubMed Web of Science ®Google Scholar
• Hallan S, Astor B, Romundstad S, et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: the HUNT II Study. Arch Intern Med. 2007;167:2490–96.
   PubMedGoogle Scholar
• Solomon SD, Lin J, Solomon CG, et al. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation. 2007;116:2687–93.
   PubMed Web of Science ®Google Scholar
• Gutierrez OM, Khodneva YA, Muntner P, et al. Association between urinary albumin excretion and coronary heart disease in black vs white adults. JAMA. 2013;310:706–14.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation. 2005;111:1370–76.
   PubMed Web of Science ®Google Scholar
• Knight EL, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis. 2003;41:588–95.
   PubMed Web of Science ®Google Scholar
• Halimi JM, Hadjadj S, Aboyans V, et al. Microalbuminuria and urinary albumin excretion: French clinical practice guidelines. Diabetes Metab. 2007;33:303–09.
   PubMed Web of Science ®Google Scholar
• Parving HH, Mogensen CE, Jensen HA, Evrin PE. Increased urinary albumin-excretion rate in benign essential hypertension. Lancet. 1974;1:1190–92.
   PubMed Web of Science ®Google Scholar
• Imai Y, Obara T, Asamaya K, Ohkubo T. The reason why home blood pressure measurements are preferred over clinic or ambulatory blood pressure in Japan. Hypertens Res. 2013;36:661–72.
   PubMed Web of Science ®Google Scholar
• Agarwal R. Home and ambulatory blood pressure monitoring in chronic kidney disease. Curr Opin Nephrol Hypertens. 2009;18:507–12.
   PubMed Web of Science ®Google Scholar
• Iino Y, Hayashi M, Kawamura T, et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension–a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res. 2004;27:21–30.
   PubMed Web of Science ®Google Scholar
• Vogt L, Navis G, Koster J, et al. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005;23:2055–61.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Kumagai H, Saruta T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens. 2003;16:116–22.
   PubMed Web of Science ®Google Scholar
• Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens. 2000;13:418–26.
   PubMed Web of Science ®Google Scholar
• Coleman A, Freeman P, Steel S, Shennan A. Validation of the Omron 705IT (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol. Blood Press Monit. 2006;11:27–32.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kario K, Shimada K, et al. The Japanese society of hypertension guidelines for self-monitoring of blood pressure at home (Second Edition). Hypertens Res. 2012;35:777–95.
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
   PubMed Web of Science ®Google Scholar
• Bramlage P, Durand-Zaleski I, Desai N, et al. The value of irbesartan in the management of hypertension. Expert Opin Pharmacother. 2009;10:1817–31.
   PubMed Web of Science ®Google Scholar
• Shimamoto K, Ando K, Fujita T, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253–387.
   PubMed Web of Science ®Google Scholar
• Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–30.
   PubMed Web of Science ®Google Scholar
• Agewall S, Persson B, Samuelsson O, et al. Microalbuminuria in treated hypertensive men at high risk of coronary disease. The Risk Factor Intervention Study Group. J Hypertens. 1993;11:461–69.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.
   PubMed Web of Science ®Google Scholar
• Matsui Y, Eguchi K, Ishikawa J, et al. Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker. Am J Hypertens. 2011;24:466–73.
   PubMed Web of Science ®Google Scholar
• Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198–202.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008;73:1303–09.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Wakino S, Sugano N, et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007;100:342–53.
   PubMed Web of Science ®Google Scholar
• Herlitz H, Harris K, Risler T, et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant. 2001;16:2158–65.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173–81.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Carrero JJ, Martin-Ventura JL, et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol. 2010;5:1174–81.
   PubMed Web of Science ®Google Scholar
• Fujita T, Ando K, Nishimura H, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007;72:1543–49.
   PubMed Web of Science ®Google Scholar
• Williams DM, Cubeddu LX. Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol. 1988;28:990–94.
   PubMed Web of Science ®Google Scholar
• Lefebvre J, Poirier L, Archambault F, et al. Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study. Can J Cardiol. 1998;14:682–88.
   PubMed Web of Science ®Google Scholar
• Zannad F, Bernaud CM, Fay R. Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension. General Physicians Investigators’ Group. J Hypertens. 1999;17:137–46.
   PubMed Web of Science ®Google Scholar
• Takano K, Fukui Y. Effect of efonidipine hydrochloride, Landel tablet, on 24 hour ambulatory blood pressure (in Japanese). J Blood Press (Ketsuatsu). 2010;17:861–65.
   Google Scholar
• Bidani AK, Griffin KA. Calcium channel blockers and renal protection: is there an optimal dose? J Lab Clin Med. 1995;125:553–55.
   PubMed Web of Science ®Google Scholar
• Zelmanovitz T, Gross JL, Oliveira JR, et al. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care. 1997;20:516–19.
   PubMed Web of Science ®Google Scholar